GlassScriptPhysician profile
Jeffrey R Thompson
NPI 1285617860
$5,469.10
in general payments reported to CMS, 2019-2025
29 companies · $989 in 2025
The $989 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $257 · 2021: $526 · 2022: $658 · 2023: $1,392 · 2024: $1,015 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,930 · Consulting Fee: $465 · Education: $1.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.07 |
| Consulting Fee | $465.43 |
| Education | $1.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $699.43 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $587.35 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $569.65 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $514.98 | 2019-2025 | Farxiga |
| Amgen INC. | $400.36 | 2021-2025 | Krystexxa, Tavneos, Parsabiv |
| Mallinckrodt Hospital Products INC. | $395.11 | 2020-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $294.43 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $218.24 | 2021-2025 | |
| Horizon Therapeutics Plc | $168.44 | 2023 | Krystexxa |
| Novo Nordisk INC | $166.85 | 2021-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $155.28 | 2024-2025 | |
| Genentech USA, INC. | $154.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.31 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $128.38 | 2024-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $127.25 | 2019-2023 | Veltassa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $115.16 | 2019-2024 | Velphoro |
| Akebia Therapeutics INC | $99.85 | 2019-2025 | Vafseo |
| Travere Therapeutics, INC. | $99.01 | 2023-2025 | |
| Abiomed | $93.85 | 2024 | Impella |
| Ardelyx, INC. | $82.14 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $45.73 | 2025 | Jardiance |
| Veloxis Pharmaceuticals, INC. | $41.42 | 2023 | Envarsus |
| Renalytix Ai, INC. | $41.01 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Calliditas Therapeutics US INC. | $33.74 | 2025 | Tarpeyo |
| Recor Medical INC | $23.92 | 2024 | Paradise Renal Denervation System |
| Takeda Pharmaceuticals U.S.A., INC. | $21.99 | 2020 | |
| Mallinckrodt Enterprises LLC | $21.26 | 2019 | |
| Genzyme Corporation | $17.96 | 2019 | |
| Shire North American Group INC | $14.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.